Using, 68Ga-PSMA-11 PET/CT for therapy response assessment in patients with metastatic castration-resistant prostate cancer: an application of EAU/EANM recommendations in clinical practice.
Denis, Chloé; COUSIN, François; De Laere, Bramet al.
2022 • In Journal of Nuclear Medicine, 63 (12), p. 1815-1821
Flare; Oncology: GU; PET/CT; PSMA PET/CT; Prostate Cancer; Tumor quantification; mCRPC; Radiology, Nuclear Medicine and imaging
Abstract :
[en] For patients with metastatic castration-resistant prostate cancer (mCRPC), no reliable biomarkers are currently available that predict therapeutic response or assist in treatment selection and sequencing. Using the recent European Association of Urology and European Association of Nuclear Medicine (EAU/EANM) recommendations, we aimed to (1) compare response assessment between prostate-specific membrane antigen (PSMA) positron emission tomography combined with computed tomography (PET/CT) and conventional imaging (CI) in mCRPC patients starting a first-line treatment with novel hormonal agents (NHA), and (2) perform a sequential comparative analysis of PSMA PET/CT-derived parameters after 4 and 12 weeks of therapy. Methods: Eighteen mCRPC patients who started NHA and underwent 68Ga-PSMA-11 PET/CT before therapy initiation (baseline), at week 4 (W4) and week 12 (W12), in addition to CI (bone scintigraphy, CT) at baseline and W12, were retrospectively included. PET/CT images were quantitatively analyzed for maximum and mean standardized uptake value and total PSMA-ligand positive total lesion (PSMA-TL). Comparative analysis of PET/CT-derived parameters was performed, and patients were classified with non-progressive disease (non-PD) or progressive disease (PD) according to 68Ga-PSMA-11 PET/CT, PSA and CI criteria. Results: Treatment response was evaluable by 68Ga-PSMA-11 PET/CT in 16/18 (89%) patients compared to 11/18 (61%) by CI. At W12, patients with PD by 68Ga-PSMA-11 PET/CT already met progression criteria at W4 (n = 5/16) and substantial agreement was observed between the W4 and W12 (κ = 0.74) 68Ga-PSMA-11 PET/CT. Nonetheless, 2/16 (13%) patients were wrongly classified with PD due to a flare phenomenon on PSMA PET/CT, which disappeared at W12. Conclusion: Volumetric assessments of 68Ga-PSMA-11 PET/CT imaging can improve response evaluation in NHA-treated patients with mCRPC. Although early response assessments at W4 need to be approached with caution due to flare, 68Ga-PSMA-11 PET/CT imaging at 4 and 12 weeks revealed a substantial agreement in the therapy response assessment, which warrants further investigation to distinguish PD from flare at W4 and help improve our understanding of resistance to therapy.
Disciplines :
Oncology
Author, co-author :
Denis, Chloé ; Centre Hospitalier Universitaire de Liège - CHU > > Service d'oncologie médicale
COUSIN, François ; Centre Hospitalier Universitaire de Liège - CHU > > Service médical de médecine nucléaire et imagerie onco
De Laere, Bram; Ghent University, Belgium
HUSTINX, Roland ; Centre Hospitalier Universitaire de Liège - CHU > > Service médical de médecine nucléaire et imagerie onco
SAUTOIS, Brieuc ✱; Centre Hospitalier Universitaire de Liège - CHU > > Service d'oncologie médicale
WITHOFS, Nadia ✱; Centre Hospitalier Universitaire de Liège - CHU > > Service médical de médecine nucléaire et imagerie onco
✱ These authors have contributed equally to this work.
Language :
English
Title :
Using, 68Ga-PSMA-11 PET/CT for therapy response assessment in patients with metastatic castration-resistant prostate cancer: an application of EAU/EANM recommendations in clinical practice.
Abuzallouf S, Dayes I, Lukka H. Baseline staging of newly diagnosed prostate cancer: a summary of the literature. J Urol. 2004;171:2122–2127.
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–247.
Hofman MS, Lawrentschuk N, Francis RJ, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multi-centre study. Lancet. 2020;395:1208–1216.
Perera M, Papa N, Christidis D, et al. Sensitivity, specificity, and predictors of positive 68Ga–prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis. Eur Urol. 2016; 70:926–937.
Mottet N, Cornford P, Van den Bergh RCN, et al. EAU-ESTRO-ESUR-SIOG guidelines on prostate cancer. Paper presented at: EAU Annual Congress Amsterdam; July 17–26, 2020; Arnhem, The Netherlands.
Fanti S, Goffin K, Hadaschik BA, et al. Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer. Eur J Nucl Med Mol Imaging. 2021;48:469–476.
Paschalis A, Sheehan B, Riisnaes R, et al. Prostate-specific membrane antigen heterogeneity and DNA repair defects in prostate cancer. Eur Urol. 2019;76:469–478.
Kaittanis C, Andreou C, Hieronymus H, et al. Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling through metabotropic glutamate receptors. J Exp Med. 2018;215:159–175.
Emmett L, Yin C, Crumbaker M, et al. Rapid modulation of PSMA expression by androgen deprivation: serial 68Ga-PSMA-11 PET in men with hormone-sensitive and castrate-resistant prostate cancer commencing androgen blockade. J Nucl Med. 2019;60:950–954.
Mei R, Bracarda S, Emmett L, et al. Androgen deprivation therapy and its modulation of PSMA expression in prostate cancer: mini review and case series of patients studied with sequential 68Ga-Ga-PSMA-11 PET/CT. Clin Transl Imaging. 2021;9: 215–220.
Kyriakopoulos CE, Heath EI, Ferrari A, et al. Exploring spatial-temporal changes in 18F-sodium fluoride PET/CT and circulating tumor cells in metastatic castration-resistant prostate cancer treated with enzalutamide. J Clin Oncol. 2020;38:3662–3671.
Berghen C, Joniau S, Ost P, et al. Progression-directed therapy for oligoprogression in castration-refractory prostate cancer. Eur Urol Oncol. 2021;4:305–309.
Triggiani L, Mazzola R, Magrini SM, et al. Metastasis-directed stereotactic radiotherapy for oligoprogressive castration-resistant prostate cancer: a multicenter study. World J Urol. 2019;37:2631–2637.
Scher HI, Morris MJ, Stadler WM, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncol. 2016;34:1402–1418.
Derwael C, Lavergne O, Lovinfosse P, et al. Interobserver agreement of 68Ga-Ga-PSMA-11 PET/CT images interpretation in men with newly diagnosed prostate cancer. EJNMMI Res. 2020;10:15.
Acar E, Özdoğan Ö, Aksu A, Derebek E, Bekiş R, Kaya GÇ. The use of molecular volumetric parameters for the evaluation of Lu-177 PSMA I&T therapy response and survival. Ann Nucl Med. 2019;33:681–688.
Ferdinandus J, Violet J, Sandhu S, et al. Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617. Eur J Nucl Med Mol Imaging. 2020;47:2322–2327.
Violet J, Jackson P, Ferdinandus J, et al. Dosimetry of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: correlations between pretherapeutic imaging and whole-body tumor dosimetry with treatment outcomes. J Nucl Med. 2019;60:517–523.
Sheikhbahaei S, Afshar-Oromieh A, Eiber M, et al. Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging. Eur J Nucl Med Mol Imaging. 2017;44:2117–2136.
Seifert R, Herrmann K, Kleesiek J, et al. Semiautomatically quantified tumor volume using 68Ga-PSMA-11 PET as a biomarker for survival in patients with advanced prostate cancer. J Nucl Med. 2020;61:1786–1792.
Gafita A, Bieth M, Kronke M, et al. qPSMA: semiautomatic software for whole-body tumor burden assessment in prostate cancer using 68Ga-PSMA11 PET/CT. J Nucl Med. 2019;60:1277–1283.
Farolfi A, Hirmas N, Gafita A, et al. PSMA-PET identifies PCWG3 target populations with superior accuracy and reproducibility when compared to conventional imaging: a multicenter retrospective study. J Nucl Med. 2021;62: 675–678.
Schmuck S, von Klot CA, Henkenberens C, et al. Initial experience with volumetric 68Ga-PSMA I&T PET/CT for assessment of whole-body tumor burden as a quantitative imaging biomarker in patients with prostate cancer. J Nucl Med. 2017; 58:1962–1968.
Noto B, der Springe KA, Huss S, Allkemper T, Stegger L. Prostate-specific membrane antigen–negative metastases: a potential pitfall in prostate-specific membrane antigen PET. Clin Nucl Med. 2018;43:e186–e188.
Cook GJR, Venkitaraman R, Sohaib AS, et al. The diagnostic utility of the flare phenomenon on bone scintigraphy in staging prostate cancer. Eur J Nucl Med Mol Imaging. 2011;38:7–13.
Gupta M, Choudhury PS, Rawal S, Goel HC, Rao SA. Evaluation of RECIST, PERCIST, EORTC, and MDA criteria for assessing treatment response with Ga68-PSMA PET-CT in metastatic prostate cancer patient with biochemical progression: a comparative study. Nucl Med Mol Imaging. 2018;52:420–429.
Andrei G, Isabel R, Manuel W, et al. Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP): an international multicenter study. J Clin Oncol. 2022; 40(6 suppl):42.
Buteau PJ, Martin JA, Louise E, et al. PSMA PET and FDG PET as predictors of response and prognosis in a randomized phase 2 trial of 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic, castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603). J Clin Oncol. 2022; 40(6 suppl):10.
Conteduca V, Wetterskog D, Scarpi E, et al. Plasma tumor DNA as an early indicator of treatment response in metastatic castration-resistant prostate cancer. Br J Cancer. 2020;123:982–987.
